Integra Lifesciences Holdings Corp (IART) : Sector Gamma As scooped up 54,024 additional shares in Integra Lifesciences Holdings Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 27, 2016. The investment management firm now holds a total of 301,457 shares of Integra Lifesciences Holdings Corp which is valued at $22.3 Million.Integra Lifesciences Holdings Corp makes up approximately 4.18% of Sector Gamma As’s portfolio.
Other Hedge Funds, Including , D. E. Shaw reduced its stake in IART by selling 11,144 shares or 12.99% in the most recent quarter. The Hedge Fund company now holds 74,649 shares of IART which is valued at $5.4 Million. Integra Lifesciences Holdings Corp makes up approx 0.01% of D. E. Shaw’s portfolio.Victory Capital Management Inc reduced its stake in IART by selling 39,046 shares or 10.65% in the most recent quarter. The Hedge Fund company now holds 327,493 shares of IART which is valued at $23.3 Million. Integra Lifesciences Holdings Corp makes up approx 0.10% of Victory Capital Management Inc’s portfolio. Sg Americas Securities added IART to its portfolio by purchasing 2,384 company shares during the most recent quarter which is valued at $169,383.Netols Asset Management reduced its stake in IART by selling 16,223 shares or 11.87% in the most recent quarter. The Hedge Fund company now holds 120,399 shares of IART which is valued at $8.6 Million. Integra Lifesciences Holdings Corp makes up approx 1.94% of Netols Asset Management’s portfolio.
Integra Lifesciences Holdings Corp opened for trading at $76.77 and hit $77.3 on the upside on Tuesday, eventually ending the session at $76.72, with a gain of 0.13% or 0.1 points. The heightened volatility saw the trading volume jump to 3,29,989 shares. Company has a market cap of $2,855 M.
On the company’s financial health, Integra Lifesciences Holdings Corp reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.73. The company had revenue of $236.80 million for the quarter, compared to analysts expectations of $230.83 million. The company’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.76 EPS.
Many Wall Street Analysts have commented on Integra Lifesciences Holdings Corp. Company shares were Reiterated by Barclays on Apr 28, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 74 from a previous price target of $70 .
Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.